An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review
Bacterial vaginosis (BV) is the most common vaginal disorder in reproductive-age women. The condition is characterised by the replacement of a healthy, lactobacilli-dominated vaginal microbiota by anaerobic and facultative anaerobic bacteria. BV increases the risk of acquisition of STIs and is associated with pregnancy complications. Although the composition of the bacteria in BV varies between individuals, there are some species such as Gardnerella, Atopobium, Mycoplasma, Snethia, Megasphera, Dialister, etc., that are found most frequently.
Material and Methods
Literature research to the importance of Atopobium vaginae in BV and treatment options.
Atopobium (A.) vaginae is an important component of the complex abnormal vaginal flora in BV; even though A. vaginae, like Gardnerella vaginalis, has also been detected in the normal flora, it is much more common in BV patients. A. vaginae has been shown to play an important role in the pathophysiology of BV and is thought to be at least a partial cause of the known negative sequelae. The presence of A. vaginae in the BV-associated biofilms and its resistance to some antimicrobial substances has been described - this seems to have a major impact on treatment outcome.
Current scientific data demonstrate that dequalinium chloride (Fluomycin®) is one of the valid therapeutic options for BV treatment, since it displays a broad antimicrobial spectrum against relevant vaginal pathogens, especially against G. vaginalis and A. vaginae, without having safety concerns.
KeywordsBacterial vaginosis Bacterial biofilm Atopobium vaginae Metronidazole Clindamycin Dequalinium chloride Microbial resistance
Bacterial vaginosis (BV) is the most common vaginal disorder in reproductive-age women . The condition is characterised by the replacement of a lactobacilli-dominated vaginal microbiota by anaerobic and facultative anaerobic bacteria. It is still unknown whether the loss of lactobacilli precedes or follows the upheaval of flora in BV . However, it seems to be quite certain that it is a preferential proliferation of the BV-related bacteria, rather than an exogenous acquisition .
Only some women with BV have symptoms, displaying a malodorous, watery, grey discharge. Because of the absence of inflammation, BV is not called vaginitis—there is no pain, no itching, no dyspareunia, no redness of the vulva or vagina, and no toxic leucocytes—only a microbial shift to anaerobic pathogens . However, BV increases the risk of acquisition and transmission of STIs  and is associated with adverse obstetric and gynaecologic outcomes including miscarriage, premature labour, preterm birth, preterm prelabour rupture of membranes, chorioamnionitis, intrauterine infection, post-caesarean endometritis, upper genital tract infections, and pelvic inflammatory disease [5, 6].
Although the composition of the bacteria in BV varies between individuals, Gardnerella, Atopobium, Mycoplasma, Prevotella, Bifidobacterium, Megasphaera, Leptotrichia, Sneathia, Dialister, Clostridium, and Bacterial Vaginosis-Associated Bacterium (BVAB)-1, -2 and -3 species are found most frequently [7, 8]. The association of G. vaginalis with BV was originally described by Gardner and Dukes already in 1955 . G. vaginalis and Prevotella spp. are found in the disturbed vaginal microbiome, but they are also present in lower loads in healthy women [7, 10]. However, the involvement of A. vaginae in BV, although it rarely occurs in the absence of G. vaginalis, has only been established in recent years [11, 12, 13]. Increasing evidence on its involvement in BV biofilm formation, as well as on specific resistances of A. vaginae against standard antibiotics may explain therapeutic failures and recurrences of BV .
Despite the current knowledge on BV many questions regarding treatment remain unanswered—all current therapies have disadvantages and gaps . This mini review describes the current scientific knowledge regarding the relevance of A. vaginae in the pathogenesis of BV and what should be considered when choosing a treatment.
Role of A. vaginae in BV
Only recently, the association of A. vaginae with BV was reported [11, 12] and many subsequent studies have confirmed the bacterium to be an important component of the complex abnormal vaginal flora in BV [11, 12, 18, 19, 20, 21]. Even though A. vaginae, as G. vaginalis, has also been detected in the normal vaginal flora (8%  up to 25% ), it is found much more commonly in BV patients (50% , 55% , 83% , 96% ). Also, the differences between African and Caucasian women, referring the prevalence of A. vaginae in the first ones have been described . Loads of G. vaginalis, A. vaginae, and other typical BV-pathogens are significantly higher in the BV-positive group than in healthy controls . Additionally, A. vaginae has been positively associated with BV typical vaginal discharge, an elevated pH and the presence of clue cells [18, 24]. It was also described that high vaginal loads of A. vaginae in combination with G. vaginalis are associated with late miscarriage and prematurity [6, 25]. Additionally, it was demonstrated using an in vitro model that A. vaginae stimulates an innate immune response from epithelial cells, leading to localised IL-6 and IL-8 and an antimicrobial β-defensin peptide production occurring after triggering the toll-like receptor 2, and this possibly contributes to the pathogenesis of BV . Hence, in BV G. vaginalis and A. vaginae still belong to ‘the main suspects’, a possible synergism between the two organisms has been considered, and because of this several authors using molecular-based techniques have examined the possibility of combining loads of A. vaginae and G. vaginalis as a means of diagnosing BV [15, 27, 28].
Involvement of A. vaginae in biofilm formation
Bacteria rarely exist as single-species planktonic forms but thrive in complex polymicrobial adhering communities enveloped by extracellular matrices, so-called biofilms. The bacteria account for less than 10% of biofilm mass, whereas the biofilm matrix usually accounts for more than 90% and provides the best living conditions for the bacteria . Costerton et al. in 1999  have described the association of a bacterial biofilm with various chronic infections. Regardless of the location in the human body, biofilm infections share similar clinical characteristics. They grow slowly, and bacterial communities are rarely fully destroyed by the host-defence mechanisms. Bacteria in biofilm release antigens resulting in an increase in antibody production. However, due to the biofilm structure, the produced antibodies are not capable of killing the biofilm bacteria .
The biofilm formation in BV is a virulence mechanism that enhances pathogenicity . The polymicrobial BV-biofilm can be seen with the Gram-stain method in the form of clue cells, which are vaginal epithelial cells covered by layers of adherent Gram-negative and/or -variable cells. Using fluorescence in situ hybridisation (FISH) method, the structure and composition of the biofilm can be studied in more detail , especially considering the combined presence of G. vaginalis and A. vaginae. Hardy et al. , similar to that previously described by Swidsinski et al. , have demonstrated that adherent A. vaginae and G. vaginalis were visualised in, respectively, 54% and 82% of samples with bacterial biofilm in BV. It was detected that G. vaginalis accounted for 60% or more and A. vaginae accounted for 40% or less of the film bacterial composition. It is assumed that G. vaginalis acts as an initial coloniser to establish early biofilm structures to which secondary colonisers, such as A. vaginae can attach [33, 34]. The fact that G. vaginalis is capable of displacing protective lactobacilli on pre-coated vaginal epithelial cells, is probably related to its ability to promote biofilm formation. In contrast, the other anaerobes, including A. vaginae, are easily outcompeted by L. crispatus . Hardy et al.  also demonstrated the important role of A. vaginae together with G. vaginalis in BV-associated biofilm. Interactions among these species within a biofilm are synergistic: these include co-aggregation, metabolic cooperation and increased resistance to antibiotics or host immune responses and have important clinical implications . The presence of a biofilm—due to increased resistance to treatment—is thought to be one of the possible reasons for the BV recurrence [37, 38].
Considerations on conventional treatments
Concerning the treatment options, the mainstay of BV treatment in many countries remains either oral or vaginal metronidazole once a day for 5–7 days or vaginal clindamycin as first-line treatments. The efficacy of the treatment with metronidazole is comparable to topical clindamycin . Cure rates, following intravaginal treatment with metronidazole or clindamycin, account for 70–90% at the end of treatment and 1 month after the end of therapy [3, 4, 40]. However, as it was first and best described by Larsson and Forsum in 2005 , 3 months after the treatment the recurrence rate can exceed 30% .
De Backer et al.  demonstrated that susceptibility to metronidazole varied significantly across various A. vaginae strains in vitro. Some of the investigated clinical isolates of A. vaginae were shown to be highly resistant to nitroimidazoles such as metronidazole and secnidazole [11, 43] and it was suggested that this could play a role in treatment failure [11, 42]. Susceptibility testing for metronidazole of additional A. vaginae isolates demonstrated that the minimum inhibition concentration (MIC) is variable, ranging from 2 µg/mL (sensitive) to more than 256 µg/mL (resistant) . So far more than half of the tested isolates were resistant.
Beigi and colleagues described a significant increase of clindamycin-resistant anaerobic bacteria after treatment . It is unclear if this is true for A. vaginae specifically. Even though these resistance findings seem to be interesting, it is questionable whether it influences clinical efficacy in patients with recurrent BV formerly treated with clindamycin. In vitro data suggest that clindamycin is effective against A. vaginae already at low concentrations .
Exploring alternative approaches
It has been shown that a high concentration of A. vaginae before treatment was associated with complete or partial failure of treatment for BV [11, 42]. Additionally, the presence of A. vaginae in the BV-associated biofilm has been described  and it seems that this knowledge has a major impact on treatment .
A recent study by Lopes dos Santos Santiago et al.  has investigated the in vitro susceptibility of A. vaginae to DQC in comparison to established substances (metronidazole and clindamycin). The MIC (minimal inhibition concentration) and MBC (minimal bactericidal concentration) range of DQC for 28 strains, belonging to 4 species of the genus Atopobium, i.e., A. minutum, A. rimae, A. parvulum, and A. vaginae, have been determined. The MIC and MBC for Atopobium spp. to DQC ranged between < 0.0625 and 2 µg/mL with an MIC90-value of 2 µg/mL. The MIC90-value for A. vaginae was demonstrated to be 0.5 µg/mL, i.e., A. vaginae was more sensitive than the other species tested. Not only was growth of A. vaginae inhibited at the MIC-levels, but the bacterial cells were also killed. The MICs of clindamycin and DQC for A. vaginae in this study were similar (sensitive), whereas the MIC of metronidazole was much higher (resistant) .
Biofilm disruption for treatment success
In the course of recent in vitro investigations, Gottschick and colleagues have screened various compounds for vaginal Biofilms (consisting of G. vaginalis): tThe antibiotics, such as metronidazole and tobramycin were effective in preventing biofilm formation, but had no effect on an established biofilm, while some antiseptic substances led to the disintegration of existing biofilms . Recent not yet published in vitro data are suggesting that DQC could be effective in disrupting the BV-biofilm under experimental conditions .
A. vaginae is an important component of the complex abnormal vaginal flora in BV. Resistance of A. vaginae to metronidazole, one of the current first-line treatments, as well as the presence of A. vaginae in the BV-associated biofilm have been described. Although more clinical data would be needed on this subject, this seems to have a major impact on BV treatment outcomes. Nevertheless, recently available scientific data confirms that DQC (Fluomizin®) is one of the valid therapeutic options for BV treatment, as it displays a broad antimicrobial spectrum against relevant vaginal pathogens, especially against G. vaginalis and A. vaginae, without having safety concerns.
The authors would like to thank Gabriela Zwyssig and Dr Philipp Grob, Medinova AG, Switzerland for their comments on the manuscript.
The author WM received a honorary for the manuscript. All authors contributed to the manuscript.
This review and online free access of the publication was sponsored by Medinova AG, Switzerland.
Compliance with ethical standards
Conflict of interest
Dr Valdas Prasauskas and Stephan Biber are employees of Medinova AG, Switzerland.
- 1.Kenyon C, Colebunders R, Crucitti T (2013) The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet GynecolGoogle Scholar
- 5.Witkin S (2014) The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOGGoogle Scholar
- 7.Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW, Ross FJ, McCoy CO, Bumgarner R, Marrazzo JM, Fredricks DN (2012) Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS ONE 7:e37818CrossRefGoogle Scholar
- 16.Collins MD, Wallbanks S (1992) Comparative sequence analyses of the 16S rRNA genes of Lactobacillus minutus, Lactobacillus rimae and Streptococcus parvulus: proposal for the creation of a new genus Atopobium. FEMS Microbiol Lett 74:235–240Google Scholar
- 17.Rodriguez Jovita M, Collins MD, Sjoden B, Falsen E (1999) Characterization of a novel Atopobium isolate from the human vagina: description of Atopobium vaginae sp. nov. Int J Syst Bacteriol 49(Pt 4):1573–1576Google Scholar
- 18.De Backer E, Verhelst R, Verstraelen H, Alqumber MA, Burton JP, Tagg JR, Temmerman M, Vaneechoutte M (2007) Quantitative determination by real-time PCR of four vaginal Lactobacillus species, Gardnerella vaginalis and Atopobium vaginae indicates an inverse relationship between L. gasseri and L. iners. BMC Microbiol 7:115Google Scholar
- 21.Verhelst R, Verstraelen H, Claeys G, Verschraegen G, Delanghe J, Van Simaey L, De Ganck C, Temmerman M, Vaneechoutte M (2004) Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis. BMC Microbiol 4:16CrossRefGoogle Scholar
- 23.Wang KD, Su JR (2014) Quantification of Atopobium vaginae loads may be a new method for the diagnosis of bacterial vaginosis. Clin Lab 60:1501–1508Google Scholar
- 32.Hardy L, Jespers V, Dahchour N, Mwambarangwe L, Musengamana V, Vaneechoutte M, Crucitti T (2015) Unravelling the bacterial vaginosis-associated biofilm: a multiplex Gardnerella vaginalis and Atopobium vaginae fluorescence in situ hybridization assay using peptide nucleic acid probes. PLoS ONE 10:e0136658CrossRefGoogle Scholar
- 33.Hardy L, Jespers V, Abdellati S, De Baetselier I, Mwambarangwe L, Musengamana V, van de Wijgert J, Vaneechoutte M, Crucitti T (2016) A fruitful alliance: the synergy between Atopobium vaginae and Gardnerella vaginalis in bacterial vaginosis-associated biofilm. Sex Transm InfectGoogle Scholar
- 34.Machado A, Cerca N (2015) Influence of biofilm formation by Gardnerella vaginalis and other anaerobes on bacterial Vaginosis. J Infect DisGoogle Scholar
- 37.Swidsinski A, Dorffel Y, Loening-Baucke V, Mendling W, Verstraelen H, Dieterle S, Schilling J (2010) Desquamated epithelial cells covered with a polymicrobial biofilm typical for bacterial vaginosis are present in randomly selected cryopreserved donor semen. FEMS Immunol Med Microbiol 59:399–404CrossRefGoogle Scholar
- 40.Livengood CH (2009) Bacterial vaginosis: an overview for 2009. Rev Obstet Gynecol 2:28–37Google Scholar
- 41.Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK (2006) High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 193:1478–1486CrossRefGoogle Scholar
- 45.Lopes dos Santos Santiago G, Grob P, Verstraelen H, Waser F, Vaneechoutte M (2012) Susceptibility testing of Atopobium vaginae for dequalinium chloride. BMC Res Notes 5:151Google Scholar
- 48.Weissenbacher ER, Donders G, Unzeitig V, de Martinez TB, Gerber S, Halaska M, Spacek J (2012) A comparison of dequalinium chloride vaginal tablets (Fluomizin(R)) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest 73:8–15CrossRefGoogle Scholar
- 49.Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS (2018) European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS 2018:956462418785451Google Scholar
- 50.Hay P (2017) Bacterial vaginosis. F1000Res 6:1761.Google Scholar
- 51.Della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G (2002) Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung 52:699–705Google Scholar
- 52.D'Auria FD, Simonetti G, Strippoli V (1989) Caratteristiche antimicrobiche di una tintura al dequalinio cloruro. Ann Ig 1:1227–1241Google Scholar
- 53.Cox WA (1965) Site of action of certain antibacterial heterocyclic quaternary ammonium compounds. Appl Microbiol 13:956–966Google Scholar
- 60.Palmeira-de-Oliveira A, Personal communication, 2018.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.